This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Mar;15(3):136.

doi: 10.1038/nrurol.2018.12. Epub 2018 Jan 31.

Prostate cancer: PROMs suggest a festival of benefits in LATITUDE

PMID: 29384521
DOI: 10.1038/nrurol.2018.12

Comment

Prostate cancer: PROMs suggest a festival of benefits in LATITUDE

Annette Fenner. Nat Rev Urol. 2018 Mar.

. 2018 Mar;15(3):136.

doi: 10.1038/nrurol.2018.12. Epub 2018 Jan 31.

Author

PMID: 29384521
DOI: 10.1038/nrurol.2018.12

No abstract available

PubMed Disclaimer

Comment on

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K. Chi KN, et al. Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8. Lancet Oncol. 2018. PMID: 29326030 Clinical Trial.

References

1. Lancet Oncol. 2018 Feb;19(2):194-206 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information